'Fantastic Four' wins battle of heroes at N. America box office
"Fantastic Four" -- starring actor-of-the-moment Pedro Pascal, Vanessa Kirby, Emmy winner Ebon Moss-Bachrach and Joseph Quinn ("Stranger Things') -- tells the story of a team of heroes trying to save a retro-futuristic world from the evil Galactus.
"This is an outstanding opening," said David A. Gross of Franchise Entertainment Research. "'Fantastic Four' was a modest and struggling superhero series; it just caught up with the biggest and the best."
"Superman," the latest big-budget action film featuring the iconic superhero from Warner Bros. and DC Studios, slipped to second place at $24.9 million, Exhibitor Relations said.
That puts the global take of the film, starring David Corenswet as the Man of Steel, over the $500 million mark.
"Jurassic World: Rebirth" -- the latest installment in the blockbuster dinosaur saga -- finished in third place at $13 million. Its worldwide total stands at $672.5 million.
The Universal film, starring Scarlett Johansson, Jonathan Bailey and Mahershala Ali, takes viewers to an abandoned island research facility, where secrets -- and genetically mutated dinosaurs -- are lurking.
"F1: The Movie," the Apple and Warner Bros. flick starring Brad Pitt as a washed-up Formula One driver who gets one last shot at redemption, moved up to fourth place at $6.2 million.
"Smurfs," the latest film featuring the adorable blue creatures and starring Rihanna as Smurfette, slipped to fifth place in only its second week in theaters with $5.4 million in North American ticket sales.
"The box office is on an excellent run that started two weeks ago," Gross said.
"These are not the good old days, but 'Fantastic Four' and 'Superman' are performing extremely well. Superheroes are showing some swagger, and it's good news for the industry."
Rounding out the top 10 were:
"I Know What You Did Last Summer" ($5.1 million)
"How to Train Your Dragon" ($2.8 million)
"Eddington" ($1.7 million)
"Saiyaara" ($1.3 million)
"Oh, Hi!" ($1.1 million)
bur-sst/ksb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
New Epstein Documents Reveal Details About His Life
Guest and Jeffrey Epstein attend the Victoria's Secret Fashion Show at the Plaza Hotel in New York City on August 1, 1995. Credit - Patrick McMullan—Getty Images Previously unseen letters to the late sex offender Jeffrey Epstein, along with photographs from inside his seven-story Manhattan mansion, were published by the New York Times on Tuesday. The tranche of pictures and letters from well-known artists and politicians offers a glimpse into the New York financier's life and relationships in the years leading up to his arrest for sex trafficking in 2019. They include messages for his 63rd birthday in 2016 from director Woody Allen, former prime minister of Israel Ehud Barak, real estate billionaire Mortimer Zuckerman, along with linguist and political activist Noam Chomsky. 'Being neighbors, my wife Soon-Yi and I have been invited for dinner many times. Always accept, always interesting. Wide variety of interesting people at every dinner just about Politicians, scientists, teachers, magicians, comedians, intellectuals, journalists…' Allen's letter reportedly says. He then likens the dinners to those at the castle to the 1931 movie adaptation of Dracula Dracula, where 'where Lugosi has three young female vampires who service the place.' Read More: A Timeline of Donald Trump and Jeffrey Epstein's Relationship as It Draws Renewed Attention Another letter from Barak and his wife reportedly describes Epstein as a 'collector of people.' The Times did not publish a scan of this letter as it did with Allen's, but reports that it concludes with a refrain that Epstein's friends may "enjoy your table for many more years to come.' TIME attempted to reach Barak, Chomsky, Zuckerman, and Allen for comment. The New York Times also published photographs from inside Epstein's mansion showing him with powerful global and financial figures Pope John Paul II, Mick Jagger, Elon Musk, Bill Clinton and Fidel Castro. They photograph a framed dollar bill signed by billionaire Bill Gates, with the caption 'I was wrong!' written on it. Also framed is the now-infamous photo of Donald Trump, First Lady Melania Trump, Epstein and Maxwell, taken in 2000, but with Maxwell not in frame. Epstein's relationship with the rich and powerful has been the subject of intense speculation in the years since his arrest and death by suicide in 2019. Read more: Is Donald Trump Named in the Epstein Files—and Why Won't the Questions Go Away? The Wall Street Journal reported last month that Trump had sent his own letter to Epstein in a book for his 50th birthday in 2003—long before his crimes became public knowledge. Trump has denied writing the letter and accompanying 'bawdy' drawing that the Journal reports is in the book, and the President sued the newspaper's parent firms Dow Jones and News Corp, its owner Rupert Murdoch, and two reporters over the report. The President has sought to play down his connection to Epstein over the years. He has said consistently that he broke off his friendship long before any allegations of his crimes came to light. He recently gave more details about the split when he said he fell out with the financier after Epstein 'stole' Virginia Giuffre, who later became a victim of Epstein, from the President's spa at Mar-a-Lago in Florida, where she worked as a 16-year-old in 2000. The Trump Administration has faced criticism for its refusal to release the so-called 'Epstein files,' after many within Trump's inner circle claimed for years that their contents would expose serious crimes by powerful people. The case has consumed both Republicans and Democrats as both parties search for answers. On Tuesday, the House Oversight Committee, led by Republicans, subpoenaed the Justice Department on files related to Epstein, calling for the DOJ to turn over all investigative materials related to his accomplice Ghislaine Maxwell's sex trafficking operation. Just last week, Maxwell was quietly moved to a minimum-security prison in Texas, soon after she met with the DOJ's Deputy Attorney General Todd Blanche, prompting anger from Democrats. Contact us at letters@
Yahoo
7 minutes ago
- Yahoo
Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™. Illustrative Image of Respiree's RS001 Wearable With its Connected Care 1Bio™ Platform The RS001 is a chest-worn device that directly measures respiration and offers passive cardio-respiratory monitoring. Originally cleared for in-patient clinical use, the RS001's use in home settings marks a significant step toward more accessible and preventive healthcare. The device connects to a cellular hub, which enables data to be visualized in real time via the connected care 1Bio™ dashboard. 'Respiration is the most predictive vital sign for clinical deterioration, yet it remains underutilized – particularly outside hospital settings,' said Dr. Gurpreet Singh, CEO and Founder of Respiree. 'This FDA 510(k) extension allows healthcare systems to passively and accurately monitor leading indicators in the home, enabling earlier interventions and reducing the overall burden on healthcare infrastructure.' The announcement follows Respiree's recent US$11.6 million Series A financing round, led by We Venture Capital and ClavystBio, which will accelerate development toward potential regulatory approvals and global market expansion. Respiree also announced plans to pursue additional FDA clearances for its proprietary AI software, aiming to integrate artificial intelligence models into the 1Bio™ platform for both inpatient and home-based care. 'These are exciting times for us,' added Dr. Singh. 'Our first 510(k) was for the wearable; this second one is for the platform. We are now focused on bringing our flagship AI models into the fold as a Software as a Medical Device (SaMD).' About Respiree Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( Media Enquiries Evangeline FuAdministrative ManagerRespiree Pte LtdEmail: evangeline@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST. The event will be webcast live and the registration link can be found here. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, Instagram, LinkedIn and Twitter/X. CONTACT: Investor Contact: Praxis Precision Medicines investors@ 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@ 617-430-7576Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
